UBP 310

Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: GluK1-selective kainate antagonist
Chemical Name: (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxy-thiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione
Purity: ≥98% (HPLC)
Citations (5)
Literature (3)

Biological Activity for UBP 310

UBP 310 is a GluK1 (formerly GLUK5) kainate receptor antagonist (IC50 = 130 nM); also blocks recombinant homomeric GluK3 (forrmerly GLUK7) receptors. Displays 12,700-fold selectivity for GluK1 (formerly GLUK5) over GluK2 (formerly GLUK6). Exhibits no activity at mGlu group I or NMDA receptors at concentrations of up to 10 μM. Apparent KD value is 18 ± 4 nM for depression of kainate responses on the dorsal root.

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

Compound Libraries for UBP 310

UBP 310 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for UBP 310

M. Wt 353.35
Formula C14H15N3O6S
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 902464-46-4
PubChem ID 6420160
Smiles CC1=CN(C[C@@H](C(O)=O)N)C(N(CC2=C(C(O)=O)SC=C2)C1=O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for UBP 310

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 7.07 20

Preparing Stock Solutions for UBP 310

The following data is based on the product molecular weight 353.35. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.2 mM 14.15 mL 70.75 mL 141.5 mL
1 mM 2.83 mL 14.15 mL 28.3 mL
2 mM 1.42 mL 7.08 mL 14.15 mL
10 mM 0.28 mL 1.42 mL 2.83 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for UBP 310

Certificate of Analysis / Product Datasheet
Select another batch:

References for UBP 310

References are publications that support the biological activity of the product.

Mayer et al (2006) Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J.Neurosci. 26 2852 PMID: 16540562

Dolman et al (2007) Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: Role of the substituent at the 5-position of the uracil ring in development of highly potent and selective GLUK5 kainate receptor antagonists. J.Med.Chem. 50 1558 PMID: 17348638

Perrais et al (2009) Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology 56 131 PMID: 18761361

If you know of a relevant reference for UBP 310, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Kainate Receptor Antagonists

Keywords: UBP 310, UBP 310 supplier, UBP310, kainate, receptors, antagonists, GLUK5, iGlu, ionotropic, glutamate, GluK1, Kainate, Receptors, 3621, Tocris Bioscience

5 Citations for UBP 310

Citations are publications that use Tocris products. Selected citations for UBP 310 include:

Takeshi et al (2017) Kinetics of Releasable Synaptic Vesicles and Their Plastic Changes at Hippocampal Mossy Fiber Synapses. Neuron 96 1033-1040.e3 PMID: 29103807

Anna L et al (2021) Slow AMPA receptors in hippocampal principal cells. Cell Rep 36 109496 PMID: 34348150

Buldyrev et al (2012) Synaptic pathways that shape the excitatory drive in an OFF retinal ganglion cell. J Neurophysiol 107 1795 PMID: 22205648

Pollok and Reiner (2020) Subunit-selective iGluR antagonists can potentiate heteromeric receptor responses by blocking desensitization Proc Natl Acad Sci USA 117 25851 PMID: 32999066

Do you know of a great paper that uses UBP 310 from Tocris? Please let us know.

Reviews for UBP 310

There are currently no reviews for this product. Be the first to review UBP 310 and earn rewards!

Have you used UBP 310?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.